bluebird publishes LentiGlobin data for beta thalassemia

bluebird bio Inc. (Cambridge, Mass.) reported data from the first patient treated with its LentiGlobin gene therapy in an ongoing Phase I/II trial. At 33 months post-gene transfer, an adult male patie...